Sukeyuki Nakamura

Funabashi, 2738588, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Rechallenge chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel for patients with non-small cell lung cancer and interstitial lung disease: A multicenter retrospective study.

Rechallenge chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel for patients with non-small cell lung cancer and interstitial lung disease: A multicenter retrospective study.

Journal: Cancer treatment and research communications

Published: November 12, 2025

Rechallenge of immune checkpoint inhibitor after local therapy for immune checkpoint inhibitor-resistant non-small cell lung cancer.

Rechallenge of immune checkpoint inhibitor after local therapy for immune checkpoint inhibitor-resistant non-small cell lung cancer.

Journal: Chinese clinical oncology

Published: January 20, 2025

A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment.

A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment.

Journal: Chinese clinical oncology

Published: December 12, 2023

Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients.

Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients.

Journal: Journal of clinical immunology

Published: June 07, 2023

Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1.

Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 28, 2023

Drastic response to rechallenge with calboplatin plus nab-paclitaxel after immunotherapy in a patient with advanced thymic carcinoma.

Drastic response to rechallenge with calboplatin plus nab-paclitaxel after immunotherapy in a patient with advanced thymic carcinoma.

Journal: Respiratory investigation

Published: March 01, 2023

Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2-induced lung exudative vasculitis and predicts COVID-19 severity.

Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2-induced lung exudative vasculitis and predicts COVID-19 severity.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 27, 2022

A Randomized Phase 2 Study of 5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate for the Prevention of Nephrotoxicity Induced by Cisplatin-Based Chemotherapy of Lung Cancer.

A Randomized Phase 2 Study of 5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate for the Prevention of Nephrotoxicity Induced by Cisplatin-Based Chemotherapy of Lung Cancer.

Journal: Oncology

Published: June 30, 2022

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease.

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease.

Journal: Internal medicine (Tokyo, Japan)

Published: May 12, 2020

Drastic Response of Rechallenge of Nivolumab in a Patient with NSCLC Who Progressed on the First Nivolumab Treatment.

Drastic Response of Rechallenge of Nivolumab in a Patient with NSCLC Who Progressed on the First Nivolumab Treatment.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 12, 2019

Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer.

Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer.

Journal: Thoracic cancer

Published: July 22, 2019

Pemetrexed Plus Platinum for Patients With Advanced Non-small Cell Lung Cancer and Interstitial Lung Disease.

Pemetrexed Plus Platinum for Patients With Advanced Non-small Cell Lung Cancer and Interstitial Lung Disease.

Journal: In vivo (Athens, Greece)

Published: July 19, 2019

Showing 1-12 of 18

Last Updated: 09/26/2026